Cargando…
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment dis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909869/ https://www.ncbi.nlm.nih.gov/pubmed/35267450 http://dx.doi.org/10.3390/cancers14051143 |
_version_ | 1784666299213807616 |
---|---|
author | Canale, Matteo Andrikou, Kalliopi Priano, Ilaria Cravero, Paola Pasini, Luigi Urbini, Milena Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Ulivi, Paola |
author_facet | Canale, Matteo Andrikou, Kalliopi Priano, Ilaria Cravero, Paola Pasini, Luigi Urbini, Milena Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Ulivi, Paola |
author_sort | Canale, Matteo |
collection | PubMed |
description | SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment discontinuation and disease progression. Tumor protein 53 (TP53) mutations are the most common mutations in NSCLC, and several reports highlighted a role for these mutations in influencing prognosis and responsiveness to EGFR targeted therapy. In this review, we discuss the emerging data about the role of TP53 in predicting EGFR mutated NSCLC patients’ prognosis and responsiveness to targeted therapy. ABSTRACT: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment. |
format | Online Article Text |
id | pubmed-8909869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89098692022-03-11 The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy Canale, Matteo Andrikou, Kalliopi Priano, Ilaria Cravero, Paola Pasini, Luigi Urbini, Milena Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Ulivi, Paola Cancers (Basel) Review SIMPLE SUMMARY: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) mutations usually benefit from targeted therapy treatment. Nonetheless, primary or acquired resistance mechanisms lead to treatment discontinuation and disease progression. Tumor protein 53 (TP53) mutations are the most common mutations in NSCLC, and several reports highlighted a role for these mutations in influencing prognosis and responsiveness to EGFR targeted therapy. In this review, we discuss the emerging data about the role of TP53 in predicting EGFR mutated NSCLC patients’ prognosis and responsiveness to targeted therapy. ABSTRACT: Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment. MDPI 2022-02-23 /pmc/articles/PMC8909869/ /pubmed/35267450 http://dx.doi.org/10.3390/cancers14051143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Canale, Matteo Andrikou, Kalliopi Priano, Ilaria Cravero, Paola Pasini, Luigi Urbini, Milena Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Ulivi, Paola The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title_full | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title_fullStr | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title_full_unstemmed | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title_short | The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy |
title_sort | role of tp53 mutations in egfr-mutated non-small-cell lung cancer: clinical significance and implications for therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909869/ https://www.ncbi.nlm.nih.gov/pubmed/35267450 http://dx.doi.org/10.3390/cancers14051143 |
work_keys_str_mv | AT canalematteo theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT andrikoukalliopi theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT prianoilaria theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT craveropaola theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT pasiniluigi theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT urbinimilena theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT delmonteangelo theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT crinolucio theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT brontegiuseppe theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT ulivipaola theroleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT canalematteo roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT andrikoukalliopi roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT prianoilaria roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT craveropaola roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT pasiniluigi roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT urbinimilena roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT delmonteangelo roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT crinolucio roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT brontegiuseppe roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy AT ulivipaola roleoftp53mutationsinegfrmutatednonsmallcelllungcancerclinicalsignificanceandimplicationsfortherapy |